Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Helena W RodbardJulio RosenstockLuis H CananiChaicharn DeerochanawongJanusz GumprechtSøren Østergaard LindbergIldiko LingvayAnette Luther SøndergaardMarianne Bach TreppendahlEduard Montanyanull nullPublished in: Diabetes care (2019)
Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.